Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Status:
RECRUITING
Trial end date:
2035-12-30
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University